SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-23542"
 

Sökning: id:"swepub:oai:DiVA.org:oru-23542" > Improved health sta...

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes

Home, P. D. (författare)
Institute of Cellular Medicine, Diabetes, Newcastle University, Newcastle upon Tyne, UK
Meneghini, L. (författare)
Miller School of Medicine, University of Miami, Miami FL, USA
Wendisch, U. (författare)
Gemeinschaftspraxis für Innere Medizin und Diabetologie, Hamburg, Germany
visa fler...
Ratner, R. E. (författare)
MedStar Health Research Institute, Hyattsville MD, USA
Johansen, T. (författare)
Novo Nordisk A ⁄ S, Søborg, Denmark
Christensen, T. E. (författare)
Novo Nordisk A ⁄ S, Søborg, Denmark
Jendle, Johan, 1963- (författare)
Örebro universitet,Institutionen för hälsovetenskap och medicin,Endocrine and Diabetes Centre, Karlstad Hospital, Karlstad, Sweden
Roberts, A. P. (författare)
Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide SA, Australia
Birkeland, K. I. (författare)
Faculty of Medicine, Department of Endocrinology, Oslo University Hospital, University of Oslo, Oslo, Norway
visa färre...
 (creator_code:org_t)
2012-05-16
2012
Engelska.
Ingår i: Diabetic Medicine. - Hoboken, USA : Wiley-Blackwell. - 0742-3071 .- 1464-5491. ; 29:6, s. 716-720
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aims: The efficacy and safety of insulin degludec (degludec), a new-generation ultra-long-acting basal insulin, was compared with insulin glargine (glargine) in people with Type 1 diabetes mellitus in a 16-week, open-label, randomized trial. Health status, an important aspect of effective diabetes management, was also assessed. Methods: Degludec (n = 59) or glargine (n = 59) were injected once daily, with insulin aspart at mealtimes. Health status assessment utilized the validated Short Form 36 Health Survey, version 2, which has two summary component scores for mental and physical well-being, each comprising four domains.Results: At study end, HbA1c reductions were comparable between groups, but confirmed nocturnal hypoglycaemia was significantly less frequent with degludec [relative rate 0.42 (95% CI 0.250.69)], and overall hypoglycaemia numerically less frequent [relative rate 0.72 (95% CI 0.521.00)]. After 16 weeks, a significant improvement in Short Form 36 Health Survey mental component score of +3.01 (95% CI 0.325.70) was obtained for degludec against glargine, attributable to significant differences in the social functioning [+8.04 (95% CI 1.8914.18)] and mental health domains [+2.46 (95% CI 0.104.82)]. For mental component score, Cohens effect size was 0.42, indicating a small-to-medium clinically meaningful difference. The physical component score [+0.66 (95% CI 2.30 to 3.62)] and remaining domains were not significantly different between degludec and glargine.Conclusions: In the context of comparable overall glycaemic control with glargine, degludec improved mental well-being as measured using the mental component score of the Short Form 36 Health Survey. The improvements in overall mental component score and the underlying social functioning and mental health domains with degludec compared with glargine may relate to the observed reduction in hypoglycaemic events.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Nyckelord

Hypoglycaemia
insulin
insulin therapy
quality of life
Type 1 diabetes
Medicine
Medicin

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy